Cellphire Therapeuticsincis A Biotechnology Company Located In Rockvillemarylandfounded In 2005The Company Is Focused On Developing Innovative Hemostatic Products Aimed At Improving Outcomes In Bleeding Treatmentparticularly In Trauma And Wound Carecellphire Utilizes Proprietary Cell Stabilization Technology To Create Stabilized Cellular Therapeutics That Address Significant Unmet Needs In Acute Bleeding Scenarios The Company Has Two Primary Product Candidates In Phase 2 Clinical Studiesthrombosomesa A Freeze Dried Platelet Derived Hemostatand Cryopreserved Platelets Designed For Effective Bleeding Controlcellphire S Technology Also Explores Applications In Imagingtargeted Drug Deliveryand Regenerative Medicinewith Approximately $22 3 Million In Fundingcellphire Is Positioned For Growthanticipating The Commercial Launch Of Its Lead Asset In 2027The Company Is Committed To Ensuring That No One Dies From Controllable Hemorrhagemaking It A Significant Player In The Hemostasis Market
